Breaking Barriers: Safely Targeting Obstructive Hypertrophic Cardiomyopathy at the Source - Episode 3
Aligning With 2023 ESC Guidelines in oHCM Treatment
Published on:
Anjali Tiku Owens, MD, explores the role of cardiac myosin inhibitors in the treatment strategies for patients with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with the latest European Society of Cardiology (ESC) Guidelines released in 2023.
- Where do cardiac myosin inhibitors fit into the treatment plans of your patients with oHMC, according to the most recent guidelines? ESC Guidelines 2023
- Initiating cardiac myosin inhibitors earlier?
- Use in patients who are severely symptomatic?
- MAPLE-HCM trial
